Iovance Biotherapeutics (NASDAQ:IOVA) shares are trading higher after the company announced Lifileucel achieved an 86% response rate in a melanoma trial.

Iovance Biotherapeutics' stock is trading up 16.35% to a price of $18.79. Thursday the stock has been traded at a volume of 30.71 million, about 990.27% of its recent 30-day volume average of 3.10 million.

The stock's 50-day moving average was $30.25 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $54.21 and fallen to a low of $15.88.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.